Astragalus Astragalus mongholicus Bunge
Also called: Astragalus membranaceus (synonym), huang qi, milk vetch, beg kei
Astragalus is a flowering perennial whose root (huang qi) has been used for centuries in traditional Chinese medicine, often with other herbs. Kew's POWO lists the widely used name Astragalus membranaceus as a synonym of Astragalus mongholicus.
- Category
- Botanical
- Part used
- Root
- Strongest evidence
- C Limited
- Native range
- Native from Siberia to the Russian Far East and western and northern China (POWO: "Siberia to Russian Far East and W. & N. China")
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2025 meta-analysis (Integr Cancer Ther) included 8 RCTs (804 people with cancer) of single-herb Astragalus membranaceus preparations added to usual care; all 8 gave astragalus by injection (6 intravenous, 2 at an acupoint), 4 of them a purified astragalus polysaccharide (PG2). Six were pooled for fatigue. [8]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CKidneys and bladder1 topic
CBlood sugar and weight1 topic
CImmune system and infection1 topic
CSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood glucose in type 2 diabetes (added to metformin) | C | A 2024 review of 20 studies (953 adults) found larger falls in fasting glucose and HbA1c with astragalus plus metformin than metformin alone; most studies were low quality with bias. [1] |
| Immune response and inflammatory markers | C | A 2023 review of 19 studies (1,094 participants) reported enhanced immune responses and lower proinflammatory cytokines; the studies were small and differed widely in methods. [1] |
| Kidney measures in membranous nephropathy (added to usual therapy) | C | A 2023 review of 50 studies (3,423 participants) found greater improvement in some kidney indicators; authors cited low quality, small size and limited geographic location of the studies. [1] |
| Any health condition (overall) | C | NCCIH: there is not sufficient reliable scientific evidence to know whether astragalus is useful for any health condition. [1] |
Main constituents: Saponins (astragalosides), sterols, fatty acids, isoflavonoids and polysaccharides; no specific active ingredient has been identified [3]
Safety and side effects
- Liver (NIH LiverTox)See details
LiverTox likelihood category E (unlikely cause of clinically apparent liver injury) …
Details and sources - Pregnancy and breastfeedingNCCIH: little is known about safety during pregnancy or breastfeeding; some animal research suggests astragalus can be toxic to the fetus.
3 statements in the profile.
Details and sources - Interactions with medicines4 listed
Immunosuppressants; Tacrolimus; Blood pressure drugs and diuretics; Drugs metabolized by CYP enzymes
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications8 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada NNHPD Astragalus monograph (May 30, 2025), adults 18 and older: 9-30 g dried root per day as a decoction for traditional Chinese …
Details and sources
- May be safe when taken by mouth; up to 60 grams per day for as long as 4 months does not seem to cause adverse effects, but a thorough safety evaluation has not been done. [1]
- Because astragalus might worsen symptoms of autoimmune diseases, NCCIH states people with autoimmune diseases should avoid it. [1]
- Little is known about safety in pregnancy or breastfeeding; some animal research suggests astragalus can be toxic to the fetus. [1]
- LiverTox likelihood category E (unlikely cause of clinically apparent liver injury); no published reports of hepatotoxicity. [3]
- LactMed: astragalus is generally well tolerated, with mild gastrointestinal irritation and allergic reactions reported; no data exist on its safety in nursing mothers or infants. [4]
- Reported adverse effects include fatigue, malaise, headache and lowering of blood pressure. [2]
Interactions
| With | What happens |
|---|---|
| Immunosuppressants (e.g., tacrolimus) | May antagonize immunosuppressants; in one patient, herbal granules containing astragalus were associated with a nearly 50% fall in tacrolimus concentration. [2] |
| Blood pressure drugs | Astragalus extract can lower systolic and diastolic blood pressure and may add to antihypertensive drugs; clinical relevance not known. [2] |
| Diuretics | Showed sodium-excreting effects in a small study of healthy men and may add to diuretics. [2] |
| Anticoagulants | Constituents have anticoagulant properties that may increase bleeding risk; clinical significance not known. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements before they are marketed; firms are responsible for the safety and labeling of their products. [7]
- Canada: Health Canada's Astragalus monograph (May 30, 2025) covers oral products from the dried root of Astragalus membranaceus for adults, with traditional Chinese medicine and herbal-medicine uses. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 8 entries naming Astragalus membranaceus or Radix Astragali (earliest NDI 74 submitted 2000-02-20; most recent NDI 954 submitted 2016-10-28), most of them combinations. Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]
- Two further entries name only an unspecified "Astragalus extract" (NDI 770 submitted 2012-08-07; NDI 1428 submitted 2025-07-30), and five name Astragalus dasyanthus, a different species. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC classification of astragalus (Astragalus mongholicus / A. membranaceus) was found in the IARC Monographs list of classifications (Volumes 1–142, list updated 2026-07-23; checked 2026-10-29). [P2]
- No NTP technical report (2-year study) on astragalus (Astragalus mongholicus / A. membranaceus) was found in NTP's list of technical reports (checked 2026-10-29). [P10]
Liver (NIH LiverTox)
- LiverTox likelihood category E (unlikely cause of clinically apparent liver injury); no reports of serum enzyme elevations during therapy and no published reports of hepatotoxicity (chapter updated April 10, 2019). [P3]
Interactions with medicines
- Immunosuppressants: NCCIH: astragalus may interact with medications that suppress the immune system. [P4]
- Tacrolimus: MSK: one patient had a nearly 50% fall in tacrolimus concentration with herbal granules containing astragalus. [P5]
- Blood pressure drugs and diuretics: Possible additive blood pressure lowering and sodium excretion; clinical relevance not known. [P5]
- Drugs metabolized by CYP enzymes: LiverTox: because of possible effects on CYP activity, the potential for herb-drug interactions should be considered; clinically apparent interactions have not been reported. [P3]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) unless FDA grants an exemption petition under 111.75(a)(1)(ii) [P8]
Supply and conservation
- IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29 [P9]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada NNHPD Astragalus monograph (May 30, 2025), adults 18 and older: 9-30 g dried root per day as a decoction for traditional Chinese medicine uses; 2-4.8 g dried root per day for the immune-system and adaptogen uses. [P7]
Pregnancy and breastfeeding
- NCCIH: little is known about safety during pregnancy or breastfeeding; some animal research suggests astragalus can be toxic to the fetus. [P4]
- LactMed: no data exist on excretion into breastmilk or on safety and efficacy in nursing mothers or infants. [P6]
- Health Canada requires the label statement to ask a health care practitioner before use if pregnant or breastfeeding. [P7]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- LiverTox (NIDDK). Astragalus (last update April 10, 2019), 2019-04-10. ncbi.nlm.nih.gov
- NCCIH. Astragalus (last updated May 2025), 2025-05. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Astragalus (last updated October 22, 2026), 2026-10-22. mskcc.org
- Drugs and Lactation Database (LactMed). Astragalus (record dated June 15, 2026) (PMID 30000951), 2026-06-15. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Astragalus - Astragalus membranaceus monograph (date May 30, 2025), 2025-05-30. webprod.hc-sc.gc.ca
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Astragalus mongholicus Bunge, 2026-10-29. api.gbif.org
- National Toxicology Program. Technical Reports (list of TR studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
Sources
- NCCIH. Astragalus (last updated May 2025), 2025-05. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Astragalus (last updated October 22, 2026), 2026-10-22. mskcc.org
- LiverTox (NIDDK). Astragalus (last update April 10, 2019), 2019-04-10. ncbi.nlm.nih.gov
- Drugs and Lactation Database (LactMed). Astragalus (record dated June 15, 2026) (PMID 30000951), 2026-06-15. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Astragalus - Astragalus membranaceus monograph (date May 30, 2025), 2025-05-30. webprod.hc-sc.gc.ca
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Astragalus mongholicus Bunge (Astragalus membranaceus listed as a heterotypic synonym) (accessed 2026-10-29; native range: "Siberia to Russian Far East and W. & N. China"), 2026-10-29. powo.science.kew.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Sheng X, et al. Efficacy of Astragalus membranaceus (Huang Qi) for cancer-related fatigue: a systematic review and meta-analysis of randomized controlled studies. Integr Cancer Ther 2025;24:15347354241313344 (PMID 40302232), 2025-04-29. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.